[go: up one dir, main page]

GB201703248D0 - CHK 1 inhibition, synthetic lethality and cancer treatment - Google Patents

CHK 1 inhibition, synthetic lethality and cancer treatment

Info

Publication number
GB201703248D0
GB201703248D0 GBGB1703248.3A GB201703248A GB201703248D0 GB 201703248 D0 GB201703248 D0 GB 201703248D0 GB 201703248 A GB201703248 A GB 201703248A GB 201703248 D0 GB201703248 D0 GB 201703248D0
Authority
GB
United Kingdom
Prior art keywords
chk
inhibition
cancer treatment
synthetic lethality
lethality
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1703248.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Cancer Research Royal Cancer Hospital
Original Assignee
Institute of Cancer Research Royal Cancer Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Cancer Research Royal Cancer Hospital filed Critical Institute of Cancer Research Royal Cancer Hospital
Priority to GBGB1703248.3A priority Critical patent/GB201703248D0/en
Publication of GB201703248D0 publication Critical patent/GB201703248D0/en
Priority to PCT/EP2018/054896 priority patent/WO2018158297A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1703248.3A 2017-02-28 2017-02-28 CHK 1 inhibition, synthetic lethality and cancer treatment Ceased GB201703248D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1703248.3A GB201703248D0 (en) 2017-02-28 2017-02-28 CHK 1 inhibition, synthetic lethality and cancer treatment
PCT/EP2018/054896 WO2018158297A1 (en) 2017-02-28 2018-02-28 Chk1 inhibition, synthetic lethality and cancer treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1703248.3A GB201703248D0 (en) 2017-02-28 2017-02-28 CHK 1 inhibition, synthetic lethality and cancer treatment

Publications (1)

Publication Number Publication Date
GB201703248D0 true GB201703248D0 (en) 2017-04-12

Family

ID=58544163

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1703248.3A Ceased GB201703248D0 (en) 2017-02-28 2017-02-28 CHK 1 inhibition, synthetic lethality and cancer treatment

Country Status (2)

Country Link
GB (1) GB201703248D0 (en)
WO (1) WO2018158297A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004274013A1 (en) * 2003-09-17 2005-03-31 Icos Corporation Use of Chk1 inhibitors to control cell proliferation
EP2086644A2 (en) * 2006-11-17 2009-08-12 Schering Corporation Combination of an inhibitor of dna polymerase-alpha and an inhibitor of a checkpoint kinase for proliferative disorders

Also Published As

Publication number Publication date
WO2018158297A1 (en) 2018-09-07

Similar Documents

Publication Publication Date Title
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
ZA201905222B (en) Combination treating prostate cancer, pharmaceutical composition and treatment method
PT3576740T (en) Cancer treatment
GB201903546D0 (en) Cancer treatment
IL268463A (en) Cancer treatment
GB201706451D0 (en) Cancer treatment
ZA201804361B (en) 1,3,4-thiadiazole compounds and their use in treating cancer
IL259510A (en) 1,3,4-thiadiazole compounds and their use in treating cancer
IL275949A (en) Combination therapy for treating or preventing cancer
IL274626A (en) Cancer treatment
IL258644A (en) 1,3,4-thiadiazole compounds and their use in treating cancer
IL276074A (en) Combination therapy for treating or preventing cancer
GB201707864D0 (en) Platinum-reistant cancer treatment
IL276073A (en) Combination therapy for treating or preventing cancer
ZA202002526B (en) New alcoxyamino derivatives for treating pain and pain related conditions
SG11202006870XA (en) Combination therapy for treating or preventing cancer
SI3353164T1 (en) Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
GB201703248D0 (en) CHK 1 inhibition, synthetic lethality and cancer treatment
GB201819920D0 (en) Cancer treatment
GB201907204D0 (en) Cancer treatment 3
GB201907150D0 (en) Cancer treatment 2
GB201811431D0 (en) Cancer treatment
GB201907149D0 (en) Cancer treatment
GB201804816D0 (en) Cancer treatment
PT3580211T (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)